Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of carfilzomib in treating patients
with relapsed or refractory T-cell lymphoma. Carfilzomib may stop the growth of cancer cells
by blocking some of the enzymes needed for cell growth.
Phase:
Phase 1
Details
Lead Sponsor:
University of Nebraska
Collaborators:
Amgen National Cancer Institute (NCI) Onyx Pharmaceuticals